ANDA approval for Sirolimus Tablets
Key Takeaways
- 1Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S.
- 2FDA) for Sirolimus Tablets, 0.5mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg, and 2 mg, of PF Prism CV.
- 3According to IQVIATM sales data for the 12 month period […].
Listen to this Article
Narrated by system voice
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg, and 2 mg, of PF Prism CV.
According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg, and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark’s current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Related News:
Get the brief that 12,000+ nurses read every Tuesday
Top stories. INC updates. CNE opportunities. 5-minute read.
Double opt-in via Brevo. Unsubscribe anytime.
Read our Editorial Policy · Corrections Policy · Fact-Checking Policy
